Full TitleObservational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients with Hematologic Malignancies and with an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation
CAR T-cell therapy is a form of immunotherapy used to treat some adults with lymphoma. The treatment involves utilizing a patient’s own T cells and genetically modifying them in the laboratory to recognize a protein on their cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body.
This form of treatment is very intensive. In this study, researchers want to see how older patients respond to CAR T-cell therapy and how the treatment affects their quality of life. Patients will complete a comprehensive geriatric assessment (a review of their physical and socioeconomic health, nutrition, balance, hearing, vision, and mental health) and undergo neurocognitive testing to evaluate their attention, memory, language, reaction time, and perception. They will have these tests before treatment as well as 3 months, 6 months, and 1 year after completing CAR T-cell therapy.
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have diffuse large B-cell lymphoma that came back or continues to grow despite two or more prior regimens of therapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- Patients must be age 60 and older and be able to speak and understand English.
For more information about this study, please contact Dr. Richard J. Lin at 646-830-1008.